Journal article Open Access
Ahan Gadkari; Sofia Dash
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> <dc:contributor>Blue Eyes Intelligence Engineering and Sciences Publication (BEIESP)</dc:contributor> <dc:creator>Ahan Gadkari</dc:creator> <dc:creator>Sofia Dash</dc:creator> <dc:date>2022-01-30</dc:date> <dc:description>The availability of vaccinations against COVID-19 provides hope for containing the epidemic, which has already claimed over 2.84 million lives. However, inoculating millions of individuals worldwide would need large vaccine manufacturing followed by fair distribution. A barrier to vaccine development and dissemination is the developers' intellectual property rights. India and South Africa have jointly sought to the World Trade Organization that certain TRIPS rules of COVID-19 vaccines, medicines, and treatments be waived. This piece argues for such a waiver, highlighting the unique circumstances that exist. It believes that TRIPS's flexibilities are inadequate to cope with the present epidemic, particularly for nations without pharmaceutical manufacturing competence.</dc:description> <dc:identifier>https://zenodo.org/record/5804101</dc:identifier> <dc:identifier>10.35940/ijrte.E6675.011052</dc:identifier> <dc:identifier>oai:zenodo.org:5804101</dc:identifier> <dc:language>eng</dc:language> <dc:relation>issn:2277-3878</dc:relation> <dc:rights>info:eu-repo/semantics/openAccess</dc:rights> <dc:rights>https://creativecommons.org/licenses/by/4.0/legalcode</dc:rights> <dc:source>International Journal of Recent Technology and Engineering (IJRTE) 10(5) 61-65</dc:source> <dc:subject>Intellectual Property Rights, COVID-19 Vaccines, TRIPS Agreement, WTO</dc:subject> <dc:subject>ISSN</dc:subject> <dc:subject>Retrieval Number</dc:subject> <dc:title>Not Tripping over TRIPS: An Analysis of Necessity and Legality of the COVID-19 TRIPS Waiver Proposal</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> <dc:type>publication-article</dc:type> </oai_dc:dc>
Views | 40 |
Downloads | 23 |
Data volume | 6.5 MB |
Unique views | 35 |
Unique downloads | 23 |